INOVIO authorized to conduct vaccine candidate trials in Mexico

The company recently received regulatory authorization to conduct trials in Brazil and the Philippines 

INOVIO and partner Ai Di Weixin are collaborating in a global phase 3 trial in regions with insufficient supply of the new crown vaccine; focus is on Latin America, Asia and Africa 

Plymouth Mitting, Pennsylvania, September 24, 2021/PRNewswire/ - INOVIO (NASDAQ: INO), a company focused on bringing precision-designed DNA drugs to the market to treat infectious diseases, cancer and HPV A biotechnology company that protects people from related diseases, today announced that the company has been authorized by the Mexican national health regulatory agency COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) to conduct clinical trials in the country.

INNOVATE’s global phase 3 will evaluate the efficacy of INO-4800 in a two-dose regimen (2.

Dr.

The third phase of INNOVATE is based on the second phase.

INOVIO also announced in August that it was authorized to conduct two clinical trials sponsored by Ai Diweixin in China to study the use of INO-4800 and Beijing Kexing Biotech’s CoronaVac® (an inactivated new crown vaccine developed by Kexing Biotech.

About INO-4800 

INOVIO’s DNA candidate vaccine against SARS-CoV-2, INO-4800, is composed of precisely designed DNA plasmids.

About INOVIO 

INOVIO is a biotechnology company focused on bringing precision-designed DNA drugs to the market to treat infectious diseases, cancer and HPV-related diseases and protect people from them

Partners and collaborating institutions include Ai Di Weixin, Orient Lloyd, AstraZeneca, Bill and Melinda Gates Foundation, Epidemic Prevention Innovation Alliance Defense Advanced Research Project Agency/Chemical Biological Radiology and Nuclear Defense Joint Program Implementation Office/Ministry of Defense, HIV Vaccine Trial Network, International Vaccine Research Institute, Kaneka Eurogentec, Medical CBRN Defense Alliance, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, Parker Cancer Immunotherapy Research Institute, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Research Institute and Weststar Research Institute

Contact:

Media Contact: Jeff Richardson, 267-440-4211, jrichardson@inovio.

Investor Contact: Ben Matone, 484-362-0076, ben.

This press release contains certain forward-looking statements related to the company’s business, including the company’s DNA drug development and commercialization plans, the company’s expectations for the R&D program (including the planned initiation and implementation of preclinical studies and clinical trials, as well as these studies and trials.

Source: INOVIO Pharmaceuticals, Inc.